-+ 0.00%
-+ 0.00%
-+ 0.00%

Amplia, ANZGOG launch PRROSE ovarian cancer trial of narmafotinib plus chemotherapy

PUBT·05/10/2026 00:01:08
Listen to the news
Amplia, ANZGOG launch PRROSE ovarian cancer trial of narmafotinib plus chemotherapy
  • Amplia Therapeutics entered an agreement with ANZGOG to run an investigator-initiated PRROSE clinical trial in ovarian cancer, testing narmafotinib with standard chemotherapy.
  • Trial will enroll about 15-20 patients with high-grade serous ovarian cancer who did not respond to platinum-based chemotherapy before planned surgery.
  • Study will assess safety, then explore whether adding narmafotinib can improve post-surgical outcomes by increasing likelihood of successful tumor removal.
  • No trial results have been presented; biomarker work is planned during study to support future readouts on how drug is working.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief on May 09, 2026, and is solely responsible for the information contained therein.